31 results about "Viral type" patented technology

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The application provides a dengue virus protection and mosquito vector control antigen composition and application thereof. The antigen composition comprises a combination of dengue virus type 1-4 envelope protein domain III polypeptide and Aedes aegypti midgut mucin AaMuc1 antigen polypeptide; the amino acid sequences of the dengue virus type 1-4 envelope protein domain III polypeptide are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4; and the amino acid sequence of the Aedes aegypti midgut mucin AaMuc1 antigen polypeptide is shown as SEQ ID NO. 5. The prepared vaccine can induce the body to produce neutralizing antibodies against dengue virus type 1-4, achieve the protection of human body from dengue virus infection, induce the production of active antibodies targeting Aedes aegypti midgut mucin 1, inhibit and kill the dengue virus transmission vector Aedes aegypti, and achieve the dual prevention and control of dengue fever from two dimensions of infection prevention and transmission interruption.

The present disclosure relates to a BCG based therapeutic agent using a BCG strain that overexpresses the STING agonist, c-di-AMP. This BCG strain, called BCG-disA-OE, enhances the elevated trained immunity of macrophages and promotes early anti-viral Type I interferon responses in a subject, providing protection against viral infections such as primary respiratory infections and SARS-CoV-2 infection.

The invention relates to key antigen epitope screening, in particular to an echovirus 18 type key antigen epitope peptide and application thereof. The result of an enzyme-linked immunosorbent assay shows that Epitope 1 (SEQ ID NO: 1) can be effectively combined with E18-VP1 antiserum, and the combining capacity is obviously higher than that of Epitope 2 in a blank control and a negative result, so that one antigen epitope peptide is screened based on the complete sequence of the echovirus 18-VP1, and the antigen epitope peptide has important guiding significance for research and development of echovirus 18 vaccines.

Described herein are systems and methods that may be used to differentially detect viral serotype specific nucleic acid. For example, these systems may comprise multiple DNA-nanostructures, capture oligonucleotides and protector oligonucleotides, wherein each DNA-nanostructure and its associated capture oligonucleotide and protector oligonucleotide are specific for a unique viral type or serotype.

The invention belongs to the technical field of veterinary biology, and particularly relates to a swine foot and mouth disease virus O-type immune peptide fusion protein as well as a preparation method and application thereof. The invention provides a swine foot and mouth disease virus O-type immune peptide fusion protein. The swine foot and mouth disease virus O-type immune peptide fusion protein has an amino acid sequence as shown in SEQ ID NO: 1. The technical problems that in the prior art, antigen peptides adopted in FMDV-O immunization are insufficient in immunity and insufficient in protective efficacy are solved.

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

The application discloses a dengue virus armored RNA standard substance and a preparation method and application thereof, and belongs to the technical field of virus detection. The dengue virus armored RNA standard substance comprises a virus-like particle shell formed by self-assembly of capsid proteins of phage MS2 and an internal encapsulated dengue virus 3' untranslated region partial sequence fragment; and the nucleotide sequence of the dengue virus 3' untranslated region partial sequence fragment is shown as SEQ ID NO: 2. The dengue virus armored RNA standard substance provided by the application can be used for nucleic acid detection of dengue virus with the dengue virus 3' untranslated region partial sequence as a target. The standard substance has the characteristics of stable property, no biological pollution, true simulation of virus particle structure and RNase resistance, and is suitable for quality control of nucleic acid detection methods with the dengue virus (type 1-4) 3' untranslated region as a target, and evaluation of detection reagents and laboratory capacity.

This invention provides an attenuated vaccine against Coxsackievirus A6 (CVA6), its preparation method, and its application. By comparing a highly pathogenic clinical isolate (CVA6-HeB) with an attenuated strain (CVA6-TW141), the genetic basis of CVA6 virulence was systematically studied. This invention located the core virulence determinant to the P1 capsid region and identified a key lethal amino acid residue (VP3-238) that significantly weakens viral replication in target tissues. Based on this discovery, this invention designed and validated a candidate attenuated live vaccine with significantly reduced lethality.

The application discloses a foot-and-mouth disease virus type A ELISA antibody detection kit and a preparation method and application thereof. The application determines a sequence of a foot-and-mouth disease virus type A GH loop epitope polypeptide and a non-specific combination of a foot-and-mouth disease virus type O, effectively solves the non-specific combination problem through sequence reduction, obviously reduces the detection sensitivity of the type A antibody after the reduction, further improves the detection sensitivity through a form of a multi-antigen peptide to display the polypeptide sequence. Finally, the polypeptide epitope combination, the antigen coated plate containing the polypeptide epitope combination and the ELISA antibody detection kit are determined. The total coincidence rate of the kit for detecting foot-and-mouth disease inactivated vaccine immune antibodies and negative serum is as high as 95% or more, but the positive detection rate of the kit for detecting foot-and-mouth disease synthetic peptide vaccine immune antibodies is obviously improved, and the cross reaction of the kit for detecting foot-and-mouth disease virus type O vaccine and pig foot-and-mouth disease virus type O inactivated vaccine immune antibodies is effectively reduced.

This invention discloses a primer and nucleic acid mass spectrometry method for detecting dengue virus genotypes 4 based on multiplex RT-PCR, belonging to the field of gene detection service technology. The primer set includes amplification primer pairs and extension primers. The amplification primer pairs include upstream and downstream primers specific to the poly genes of dengue virus types 1-4, with sequences shown in SEQ ID NO. 1-8, respectively. The extension primers include extension primers targeting specific sites of dengue virus types 1-4, with sequences shown in SEQ ID NO. 9-12, respectively. The nucleic acid mass spectrometry method of this invention includes: nucleic acid extraction, multiplex RT-PCR amplification and enrichment, SAP purification reaction, extension reaction, desalting treatment, and mass spectrometry detection. This invention not only utilizes the high throughput and high precision advantages of nucleic acid mass spectrometry technology, but also provides a new, efficient, accurate, and reliable dengue virus genotyping detection scheme through targeted primer design and systematic process integration, providing a powerful technical tool for the accurate diagnosis, epidemic monitoring, and prevention and control of dengue fever.

The invention provides a reagent and a kit for jointly detecting four avian-derived RNA (Ribonucleic Acid) viruses. The reagent comprises an upstream primer, a downstream primer and a probe which are used for detecting H5N1, H7N9, avian paramyxovirus IX type and west nile virus. Through specific primer and probe sequences, H5N1, H7N9, avian paramyxovirus IX type and West Nile virus in a biological product can be detected at the same time only through one-time amplification in a one-tube reaction, and the detection reagent or kit has the advantages of high sensitivity, strong specificity, good repeatability and the like for four avian-derived RNA viruses, and has a wide application prospect. Mutual interference and cross reaction are avoided, and a large number of samples can be rapidly detected.

Described is a recombinant vaccine against porcine epidemic diarrhea (PED) comprising a viral vector having inserted therein an exogenous nucleotide sequence encoding an antigen site of PED virus type 2, and a pharmaceutically acceptable solvent, adjuvant and / or excipient wherein the vaccine is suitable for generating an immune response in a porcine body, the vaccine does not need to be combined with other vaccines or forms of PED virus type 2.

The application belongs to the technical field of biology, and particularly relates to a grass carp reovirus (GCRV-Ⅱ type) subunit recombinant vaccine, a preparation method and application. 274‑367 , VP5 105‑336 , NS38 143‑338 sequence fragments, and the three sequence fragments are recombined and expressed in a prokaryotic expression vector to prepare the subunit recombinant vaccine. The recombinant vaccine has high safety, strong activity and broad spectrum, and has good application potential.

The invention discloses a fluorescent quantitative PCR (Polymerase Chain Reaction) primer group and a detection kit for detecting type-2 agama herpesvirus and application of the fluorescent quantitative PCR primer group and the detection kit. According to the invention, a pair of specific primers IghV2-F and IghV2-R are designed for a gene conserved region of DNA-dependent DNA polymerase (pol) of iamyl herpesvirus type 2 (IghV2), and an SYBR Green dye fluorescent quantitative PCR detection method is established, so that the primer has the advantages of high sensitivity, high specificity, wide linear range, rapidness, simplicity, convenience, good repeatability and the like. The invention provides important technical support for herpesvirus infection monitoring, quarantine and protection work of rare and endangered lizard species, fills the blank of detection methods in the field, and is suitable for non-clinical medical fields such as scientific research, epidemiological investigation, quarantine monitoring, protection management and the like.

The invention relates to the technical field of biological detection, and discloses a primer probe group and a detection kit for simultaneously detecting three porcine pathogens. The invention firstly provides two primer probe groups for simultaneously detecting the porcine pseudorabies virus, the porcine cytomegalovirus and the porcine lymphotropic herpesvirus, one group is used for detecting the porcine lymphotropic herpesvirus type 1 and the porcine lymphotropic herpesvirus type 2, the other group is used for detecting the porcine lymphotropic herpesvirus type 2, and the other group is used for detecting the porcine lymphotropic herpesvirus type 3. And the other group of primers is used for detecting the swine lymphotropic herpesvirus type 3. Meanwhile, the invention also provides a detection kit containing the primer probe group. When being used for detection, the primer probe group has the advantages of high sensitivity, high specificity and simplicity in operation, can be used for simultaneously, quickly and accurately detecting the porcine pseudorabies virus, the porcine cytomegalovirus and the porcine lymphotropic herpesvirus type 1, the porcine cytomegalovirus type 2 and the porcine lymphotropic herpesvirus type 3, and provides an effective technical means for detecting and distinguishing the three viruses and subtypes in a laboratory.

A recombinant mutant BoV genome is provided, as well as methods of using the vector, e.g., to prepare helper-free virus.

Disclosed herein is a composition of a compound that has superior pharmacokinetics and pharmacodynamics as compared to conventional interferon. In addition, a method to use such composition to treat human T-cell leukemia virus type 1 (HTLV-1) associated diseases are also disclosed.

The present disclosure relates to polypeptides that specifically bind to Dengue virus non-structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIHYSGGTNYNPSLKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.

The application provides a reagent and kit for jointly detecting four kinds of avian RNA viruses. The reagent of the application comprises an upstream primer, a downstream primer and a probe for detecting H5N1, H7N9, avian parainfluenza virus type IX and West Nile virus. Through specific primer and probe sequences, H5N1, H7N9, avian parainfluenza virus type IX and West Nile virus in biological products can be simultaneously detected in one tube reaction through only one amplification, and the detection reagent or kit of the application has the advantages of high sensitivity, strong specificity, good repeatability and the like for the four kinds of avian RNA viruses, and has no interference and no cross reaction among each other, and can rapidly detect a large number of samples.

To provide a means for treating HTLV-1-associated myelopathy (HAM / TSP) and HTLV-1 infectious diseases by identifying important molecules on the side of infected cells and on the side of non-infected cells in the cell-cell contact infection of human T cell keukemia-1 virus (HTLV-1) and inhibiting the HTLV-1 cell-cell contact infection by inhibiting the mutual action thereof.SOLUTION: The HTLV-1 cell-cell contact infection inhibitor contains a substance inhibiting the interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).SELECTED DRAWING: None

The invention discloses a foot-and-mouth disease virus type O specific neutralizing swine monoclonal antibody and application thereof, and belongs to the technical field of biology. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is as shown in SEQ ID NO.2. The invention also provides application of the monoclonal antibody in preparation of a reagent or a kit for detecting the O-type foot-and-mouth disease virus and a medicine for preventing O-type foot-and-mouth disease virus infection. The antibody is a whole swine source, is good in safety, can specifically neutralize O-type FMDV PanAsia, Mya98 and Cathay classical pedigree strains, identifies key antigen sites as 73rd and 134 residues of VP3, can be used for O-type FMDV differential diagnosis and broad-spectrum vaccine design, and has an important application value.

The invention discloses a method for detecting beta-glucuronidase to evaluate the ability of shrimps to resist a decapod iridovirus type 1, and belongs to the technical field of biological breeding of aquatic animals. The method comprises the following steps: detecting beta-glucuronidase in a sample by qPCR (quantitative polymerase chain reaction) to obtain a 2-delta delta Ct value of the beta-glucuronidase, and evaluating the anti-decapod iridovirus type 1 capability of the shrimps according to the 2-delta delta Ct value, when the 2-delta delta Ct is less than or equal to 0.15, the resistance is evaluated to be high, when the 2-delta delta Ct is more than 0.15 and less than 0.45, the resistance is evaluated to be medium, and when the 2-delta delta Ct is more than or equal to 0.45, the resistance is evaluated to be susceptible. And through experimental verification, the prediction accuracy of unknown sample verification is more than 86.7%, and the AUC area of the ROC curve is 0.8864. In conclusion, the invention provides a standardized and operable evaluation method for macrobrachium rosenbergii disease-resistant molecular breeding.

The application relates to the technical field of deep learning, and discloses a 6-HB targeting membrane fusion inhibition peptide prediction method, device, equipment and medium, which comprises the following steps: generating a 6-HB targeting membrane fusion inhibition candidate peptide; inputting the membrane fusion inhibition candidate peptide into a pre-constructed 6-HB targeting membrane fusion inhibition peptide prediction model for classification prediction to obtain the classification result of the membrane fusion inhibition candidate peptide; the membrane fusion inhibition peptide prediction model is a two-stage transfer learning classification model, the first stage is based on sequence general features to perform binary classification prediction of antiviral peptides and non-antiviral peptides; the second stage is combined with spatial conformation features to perform binary classification prediction of membrane fusion inhibition peptides and non-membrane fusion inhibition antiviral peptides; and the classification result is screened to obtain the 6-HB targeting membrane fusion inhibition candidate peptide. The method realizes the leap from coarse-grained antiviral activity recognition to fine-grained 6-HB inhibition activity classification, and improves the prediction accuracy of the 6-HB inhibition peptide specific to the envelope virus type / subtype.

The application discloses a combined vaccine for preventing hand-foot-mouth disease, which comprises inactivated enterovirus 71 virus, and inactivated coxsackievirus A 16 virus, coxsackievirus A 10 virus and coxsackievirus A 6 virus. The application also discloses a method for preparing the combined vaccine, and the prepared vaccine has good adsorption effect and stability. The multiple antigens do not interfere with antigenicity and immunization effect of each other after immunizing an object, and have good immunogenicity and safety. The use of the combined vaccine can obviously simplify a vaccine inoculation procedure, improve inoculation efficiency and reduce cost.

The disclosure provides a mutant of enterovirus 71 and a virus-like particle thereof, and relates to the field of biological medicine.The virus-like particle of enterovirus 71 in the disclosure is obtained by modifying the structural genes VP0, VP1 and VP3 of the virus capsid protein by using computational structural biology, and completing self-assembly in vivo by a Hansenula polymorpha expression system.The mutant of enterovirus 71 and the virus-like particle thereof in the disclosure can significantly improve immunogenicity compared with the unmodified one, and have a high clinical application prospect.

The invention belongs to the technical field of biological detection, and discloses a primer pair, a probe and a kit for rapidly distinguishing mouse hepatitis virus, reovirus type III, mouse pox virus and mouse parvovirus. Meanwhile, the invention also discloses a multiple fluorescent quantitative PCR method for simultaneously detecting mouse hepatitis virus, reovirus type III, mouse pox virus and mouse parvovirus by adopting the kit. The kit comprises: a) an amplification reaction solution, b) a primer mixed solution, c) an enzyme mixed solution, and d) a positive control. The multiple real-time detection kit provided by the invention can jointly detect mouse hepatitis virus, reovirus type III, mouse pox virus and mouse parvovirus at one time, and has the advantages of rapidness, simplicity, high sensitivity and strong specificity.

A hazard factor test cassette and method. The hazard factor test cassette comprises: flow guide paths, the plurality of flow guide paths being respectively and independently communicated with a sample injection port(1) and flow guide platforms(2); each flow guide path comprises a long-distance flow guide path(3) and a short-distance flow guide path(4); the length for the long-distance flow guide paths(3) connecting the sample injection port(1) and the flow guide platforms(2) is greater than that of the short-distance flow guide paths(4); test strips for testing small-size targets are provided on the flow guide platforms(2) corresponding to the long-distance flow guide paths(3); and test strips for testing large-size targets are provided on the flow guide platforms(2) corresponding to the short-distance flow guide paths(4).The hazard factor test method uses the hazard factor test cassette for test, and comprises sequentially arranging toxin type test strips, virus type test strips and bacterium type test strips on paths from the long-distance flow guide paths(3) to the short-distance flow guide paths(4) among the short-distance flow guide paths(4) and the long-distance flow guide paths(3).

The application discloses an antibody against dengue virus NS1 protein and related products and uses thereof, the antibody has high expression and stable physical and chemical properties, can not only specifically bind to dengue virus 1-4 type NS1 protein, has no cross reaction, has high affinity, solves the technical pain points that existing dengue virus diagnostic means is complex in operation, lacks specificity and lacks a targeted treatment antibody; the antibody can be directly used for developing convenient and efficient dengue virus detection products (such as a kit, a test strip and the like), realizes early rapid screening and accurate typing of infection, can also be used as a core component to prepare a therapeutic drug, provides a novel technical scheme with high specificity, high affinity and wide applicability for prevention and control of dengue virus infection, and has important clinical conversion value and public health significance.

The invention provides application of an MNP marker combination for identifying rotaviruses which are common pathogens of diarrhea symptoms, a primer pair combination, a kit and application of the kit. The application comprises the steps that the MNP marker combination is used for identifying the pathogen rotavirus type A for the purpose of non-disease diagnosis, the MNP marker combination comprises at least one of a marker site MNP-1, a marker site MNP-2 and a marker site MNP-3, and nucleotide sequences of the marker site MNP-1, the marker site MNP-2 and the marker site MNP-3 are sequentially shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 in a sequence table. According to the application, the MNP markers are analyzed and detected by fusing the super-multiplex PCR amplification and high-throughput sequencing technology, tens of thousands of MNP markers of hundreds of samples are subjected to typing at a time, high-throughput and sensitive detection and accurate typing of rotaviruses are achieved, and the kit has the advantages of being small in sample demand amount, accurate in diagnosis result, capable of saving data amount and capable of detecting subtypes.